No CLIA Waiver For HemoCue Analyzer, FDA Panel Recommends
This article was originally published in The Gray Sheet
Executive Summary
There is too much room for error with HemoCue's white blood cell analyzer to make it suitable for point-of-care testing, FDA panelists concluded July 17